VOLUME- 3 | ISSUE- 11 NOVEMBER 2020



International Research Journal of Ayurveda & Yoga



An International Peer Reviewed Journal for Ayurveda & Yoga

SJIF Impact Factor : 5.69 ISRA Impact Factor : 1.318		ISSN:2581-785X				
Case study		Volume: 3	lssue: 11			

Ayurvedic Management of Poor Ovarian Reserve with special reference to Lowered AMH Levels- A Case Study

Dr. Arun Gupta,

Medical Officer (Ayurveda) Union territory of Jammu and Kashmir, M.S. Prasuti Tantra and Stri Roga

ABSTRACT:

A reduction in the ovarian reserve is one of the major factor involved in the female subfertility and infertility among the young couples. Poor ovarian reserve presents a treatment challenge to fertility experts especially in case of the ageing women desiring IVF. Serum Anti-mullerian hormone levels are one of the sensitive indicator of the ovarian reserve and lower levels indicate a poor outcome of IVF treatment and women with higher age and lower levels of serum AMH are referred to as poor responders. A composite treatment plan of Ayurveda entailed in *Kashyapa Samhita*, comprising of the bio-purification with the procedure *Virechana* followed by the rejuvenation and regenerative therapy with *Shatavari Shatpushpa Churna* and *Pushpa Dhanwa rasa* showed encouraging results in terms of elevating the levels of serum AMH levels. Ayurveda therefore can be used as an adjuvant and complementary to the conventional fertility treatments in order to enhance the chances of pregnancy and live birth in women with the poor ovarian reserve.

Keywords: Poor ovarian reserve, Low AMH levels, Virechana, Shatavari – Shatpushpa Chruna.

Article received on- 17 Nov Article send to reviewer on- 17 Nov Article send back to author on-27 Nov Article again received after correction on – 29 Nov

Corresponding Author : **Dr. Arun Gupta,** Medical Officer (Ayurveda) Union territory of Jammu and Kashmir, M.S. Prasuti Tantra and Stri Roga , Email-gupta.arun9@gmail.com

How to Cite the Article : Dr. Arun Gupta, Ayurvedic Management of Poor Ovarian Reserve with special reference to Lowered AMH Levels- A Case Study., IRJAY, November: 2020 Vol- 3, Issue-11; 60-66

Doi: https://doi.org/10.47223/IRJAY.2020.31114

INTRODUCTION:

The quantity and quality of the graffian follicles in primodial state in the ovaries indicate the Primodial follicular pool. A reduction in the ovarian reserve is one of the major factor involved in the female subfertility and infertility among the young couples.¹ Clinical observations confirmed that there is an accelerated decline in the ovarian reserve in the age group of 37-38 years of age, when the primodial follicular count reaches a critically below 25000.² Anti-mullerian hormone is one of the most sensitive marker of ovarian reserve and clinically more acceptable prerequisite for planning personalized ovarian stimulation.³ As per Bolonga criteria (2011) women with advanced maternal age (≥ 40 years) and AMH (0.5-1.1 ng/ml) are classified as " expected poor responsder" for ovarian stimulation in IVF cycles.⁴ Ayurveda also

endorses the conceptual framework of the age related gradual degeneration of the Artava, which is analogous to the reproductive element of a female.⁵ Α composite Ayurvedic treatment comprising therapeutic procedures and regenerative drugs can be of great help in increasing the ovarian reserve by the bio-purification and rejuvenation of the reproductive tissues. This case study represents a preliminary evidence of the therapeutic utility of Ayurvedic treatment in the management of age related poor ovarian reserve. Ayurveda management can therefore be used as a complementary approach to enhance the success of assisted reproductive techniques for fertility enhancement by optimizing the internal hormonal and biochemical milieu of the female body.

Case Presentation:

A 40 year female visited the outpatient department with complaint of failure to conceive since 2 years on July 24, 2020.

Chief Complaint: Failure to conceive even with IVF since 3 years.

History of Present Illness: According to the patient the couple has been trying to conceive since 3 years but their IVF cycle failed 2.5 years back. The couple has been married for 14 years. Menstrual history as reported by patient was normal for cycle length, days of menstrual flow, volume of bleeding and other associated symptoms. There was no significant past medical history of Diabetes mellitus, Tuberculosis, Hypothyroidism, Genital infection. Sexually transmitted disease, Prolonged illness or Trauma. Husband's semen analysis reportedly normal. Patient wanted repeat IVF but she was diagnosed with poor ovarian reserve and an expected poor responder to the ovulation induction by her gynecologist for which she sought Ayurvedic remedial measures.

Past Medical and Surgical History: Unremarkable.

Family History: Unremarkable.

Obstetric History: 1 Para 3 Gravida, History of 2 abortions, 6 weeks abortion 6 years back and 8 Weeks abortion 2.5 years back Post IVF. last child birth 12 years back , full term normal delivery per vaginally

Contraceptive history: No contraceptive had been ever used.

Coital History: Regular unprotected coitus beginning from 7th day of the menstrual period, on alternate days till next menstrual period. No history of entral or thrustal dyspareunia/ post coital bleeding.

REPORTS AVAILABLE:

USG REPORT:

July 2020: Follicular study on Day 2 revealed Antral follicular count of 5-6 follicles in both the ovaries.

September 2020: Serum Anti-Mullerian Hormone Levels- 0.41ng/mL. Lower AMH levels in this case are indicative of Diminished Ovarian reserve.

Treatment Plan:

Keeping in view the *Kapha* predominance and lifestyle of the patient following regimen is planned for the patient after the cessation of menstruation:

IRJAY IS THE OFFICIAL PUBLICATION OF BALA G PUBLICATION

Step 1: Shodhana Karma following Deepana Pachana, Snehana, Swedana.

Step 2: Rasayana Treatment

Treatment Component	Detail
Deepana Pachana after cessation of menstruation	Day 1 to 3 <i>Chitrakadi vati</i> 2 tabs twice a day with luke warm water.
Snehana Karma (Internal Oleation)	Day 4 to 9 <i>Phala ghruta</i> starting with 20ml on Day 1 of <i>snehana</i> to 140 ml on Day 9
Swedana Karma (Sudation)	Day 10 to 12 Abhyanga with Bala Taila followed by Sarvang swedana (Whole body sudation in sudation chamber) with Dashmoola Kwatha
Virechana Karma (Induction of controlled Purgation)	Day 14 Virechana for bio-purification with Eranda Taila 40 ml and Trifala Kashaya (Decoction) 200 ml. Patient passed 18 bowel movements
Samsarjana Krama (Post purgation dietary program)	Day 14 to 16 Sequential Diet Program followed for 3 days,
Rasayana Chikitsa (Rejuvenation Therapy)	Day 16 to till onset of Next menstruationShatavari Churan 3 gm, Shatpushpa Churna3 gm with Ghee.Pushpa Dhanva Rasa 500 mg 1 tab OD
Life style Modification	<i>Yoga</i> and Pranayama as advised on daily basis.

-

RESULTS:



DISCUSSION & CONCLUSION

In the present day context, unhealthy lifestyle. nutrition, obesity, sedentary lifestyle, psychological stress, use of prescription drugs, environmental and occupational exposure to the endocrine disruptors may affect the female fertility.⁶ with adverse Ageing associated is of IVF and reduction in outcomes pregnancy and live birth rate due to declining oocyte vield.⁷ Indiscrete life style and environmental factors coupled with aging may compound the pace of premature diminution of ovarian reserve. With the increasing access of to assisted fertility treatments, diagnosis of the poor ovarian reserve becomes more common especially

in the women of increasing. Acharya *Kashyapa* in his treatise *Kashyapa* Samhita endorse the idea of Virechana i.e. controlled purgation to enhance the quality of *beeja* (female gamete).⁸ Shatavari (Asparagus racemosus) and *Shatpushpa* (Anethum sowa) are the two herbs which are highly appreciated in Kashyapa Samhita for their potential to enhance the fertility and fecundity of a female.⁹ Some studies also reported the efficacy of *Phalaghrita* in elevating the diminishing levels of AMH.¹⁰ Pushpa Dhanwa rasa is a herbo-mineral preparation with clinical evidence of enhancing the chances of ovulation.¹¹ Considering the multi-factorial nature of the disorders, a composite treatment with Ayurveda therapeutics with a potential of

VOLUME- 3 | ISSUE- 11 NOVEMBER 2020

enhancing the oocyte (*Beeja*) quality and quantity is used which is reflected from the progressive increase in the AMH levels within two months of the treatment. This indicates that *Ayurvedic* management may be used as a complementary and adjuvant treatment prior to IVF procedure to enhance PHOTOGRAPHS OF REPORTS



AMH 1: BEFORE TREATMENT

Name: do V/Fenale Registration Mo: Specimen Registration Mo: Specimen Registration Mo: Specimen Registration Distr/Time: 21/Nov/2020 13:2 Specimen Registration Distr/Time: 21/Nov/2020 05:1 Press Refered By: Refered By: Ref				 G191-2430400, 2454200 St. A/C, Garutha Naper, Jamonson Mappen Sector Weiss generated agreestics.com 		
Investigation Name Result Biological Reference Range IMMUNOASSAY F5H; FOLLICLE STIMULATING HORMONE (SERUM) F6H; FOLLICLE STIMULATING HORMONE (SERUM) Kontent Rate Market Rate	Name: Age/Gender: 40 V/Female Test ID: Referred By:			Registration No.: Specimen Registration Date/Time: Specimen Receiving Date/Time: Receiving Date/Time:	21/Nov/2020 12:23PM 21/Nov/2020 12:59PM 21/Nov/2020 05:19PM	
IMMUNOASSAY FSH; FOLLICLE STIMULATING HORMONE (SERUM) PSH; FOLLICLE STIMULATING HORMONE (SERUM) Materia Rama Maria Maria Maria Status Maria Maria Maria Status Maria M	Investigation Name		Result	Biological Reference R	ange Unit	
FSH: FOLLICE STIMULATING HORMANNE 6.8 As below 10/ RACto-chemismissence interministration and the state interministration and	FSH; FOLLICLE STIM	ULATING HORMONE (SERUM	IMMUNOASS	AY	14	
Measure faster Margine Margine Pressure Pre	FSH; FOLLICLE Electro-chemilumi Reference Range: Male: Female	STIMULATING HORMONE inescence immunoassay	6.8	As below	IU/mL	
Patienterroadcould 13.9116.3 LH; LUTEINIZING HORMONE (SERUM) 6.8 - m80// Enctroad-membracecore Research and	Poticular phase: Mid cycle: Loteal phase: Pregnant;	2.50 - 10.20 3.40 - 33.40 1.50 - 9.20 < 0.30			2	
LH; LUTEINIZING HORMONE (SERUM) LH; LUTINIZING HORMONE 6.8 · mill/ Externationalisminatance Respective Mater 1,75° + 630 Fernite Mater 2,75° + 630 Fernite Respective Mater 2,75° + 630 Fernite Respective Mater 2,75° + 750 Fernite Respective Mater 2,75° + 750 Fernite Respective Fernite Fern	Paitmenopausal	23.0-116.3				
LH; LEUTINIZING HORMONE 6.8 millu Ricotademension Material Reference Reage: Material 129 - 8.0 Fermine - Marcing Parent 129 - 8.0 - Marcing Parent 200 - 9.0 - Marc	LH; LUTEINIZING H	ORMONE (SERUM)			4	
Bioinplay fairference Range: Mate: 1.75 • 6.80 Mate: 1.75 • 6.80 Mate: 1.75 • 1.80 Mate: 6.75 • 1.83 - Umary Javas: 5.56 • 5.48 - Grantspilowit 5.50 • 5.48 - Grantspilowit 5.70 • 5.48 - Grantspilowit 5.70 • 5.48 - Grantspilowit 6.70 • 5.48 - Grantspilowit 5.70 • 5.48 - Grantspilowit 6.70 • 5.48 <	LH; LEUTINIZI Electrochemilumi		6.8	~	mIU/mL	
- Reference Parame 1, 500 - 11-30 - Mer optier 1, 500 - 11-30 - Mar optier 1, 500 - 11-30 - Mar optier 1, 500 - 11-30 - Mer optier 1, 500 - 11-30 - Centralegiblem 1, 500 - 11-40 - Andrik ANTI MULIERIAN HORMONE (SERUM) Andri: ANTI MULIERIAN HORMONE 1,44 0,031-7.15 PE Electro- demainmentance minimumonatory	Biological Reference Male: Female:	e Range: 1.JD - 8.40				
AMH; ANTI MULLERIAN HORMONE (SERUM) AMH; ANTI MULLERIAN HORMONE 1.44 0.03 - 7.15 ne Eletto-deminimizerane immunoassay	Policular phase: Mid cycle: Lutesi phase: Prepart: Produmentariai: Contraceptivesi	1.90 - 12.30 8.70 - 76.38 0.30 - 16.59 < 0.10 15.90 - 54.00 0.70 - 5.60				
AMH; ANTI MULLERIAN HORMONE 1.44 0.03 - 7.15 ne Electro-chemiluminescence immunoassay	AMH; ANTI MULLE	RIAN HORMONE (SERUM)				
	AMH; ANTI M Electro-chemilum	ULLERIAN HORMONE	1.44	0.03 - 7.15	ng/mL	

the ovarian reserve and chances of pregnancy and live birth.

Acknowledgement:- Nil Financial Assistant:- Nil Conflict of interest :- Nil

<image>

AMH 3: After Shodhana and Rasayana Treatment

IRJAY IS THE OFFICIAL PUBLICATION OF BALA G PUBLICATION

REFERENCES:

- Jirge PR. Poor ovarian reserve. J Hum Reprod Sci. 2016 Apr-Jun;9(2):63-9. doi: 10.4103/0974-1208.183514. PMID: 27382229; PMCID: PMC4915288.
- Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: Implications for forecasting menopause. Hum Reprod. 1992;7:1342– 6.
- **3.** La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: From theory to practice. Hum Reprod Update. 2014;20:124–40.
- 4. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L ESHRE Working Group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for *in vitro* fertilization: The Bologna criteria. Hum Reprod. 2011;26:1616–24
- Sri Dalhana Acharya Edited by Vd. Yadavji Trikamji Acharya Sushruta Samhita of Sushruta with Nibandh samgraha commentary, Reprint 2017, Sutra sthana, Shonitvarneeyadhyayam, 6, 19 pp. 59, 64.
- Sharma R, Biedenharn KR, Fedor JM, Agarwal A. Lifestyle factors and reproductive health: taking control of your fertility. Reprod Biol Endocrinol. 2013 Jul 16;11:66. doi: 10.1186/1477-7827-11-66. PMID: 23870423; PMCID: PMC3717046.
- Galey-Fontaine J, Cédrin-Durnerin I, Chaïbi R, Massin N, Hugues JN. Age and ovarian reserve are distinct predictive factors of cycle outcome in low responders. Reprod Biomed Online. 2005;10:94–9.
- 8. Premavati Tiwari, Kashypa Samhita, English Translation, Chaukhamba Sanskrit Samsthana, Varanasi, 1996, Siddhi sthana, 2/7 266-267.
- **9.** Satyapal Bhishagacharya, Kashayap Samhita by Marishi Kashyap, commentary 6th edition1998, published by Chaukhamba Sanskrit sansthan, Varanasi 221001,p-185187
- Muraleedharan A, Unnikrishnan P, Narayan P, Krishnarajabhatt HS. An Ayurvedic treatment protocol to improve anti-mullerian hormone: A prerequisite for assisted reproductive technique- A case report. Ayu. 2017 Jan-Jun;38(1-2):66-69. doi: 10.4103/ayu.AYU_167_17. PMID: 29861596; PMCID: PMC5954262.
- Dhanshree Deshpande and Asokan V, A Review On Pushpadhanva Rasa In Vandhyatva (Anovulatory Factor Of Infertility), World Journal of Pharmaceutical and Life Sciences, 5(8), 2019, p-221-224.